Metoprolol Succinate is a beta-1 selective adrenergic blocker indicated for hypertension, angina pectoris and heart failure. We supply it to US manufacturers of extended-release tablets.
Data from PubChem (CID 62937) and FDA’s substance registry
CAS number
98418-47-4
Molecular formula
C34H56N2O10
Molecular weight
652.8g/mol
FDA UNII
IUPAC name
butanedioic acid;bis(1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol)
InChIKey
RGHAZVBIOOEVQX-UHFFFAOYSA-N
- Appearance
- White crystalline powder.
- Solubility
- Freely soluble in water, soluble in methanol and sparingly soluble in ethanol. Practically insoluble in ethyl acetate, acetone and heptane.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Used almost entirely in extended-release products, where particle size affects pellet coating and drug release. Strengths are labeled as metoprolol tartrate equivalents: 23.75 mg of the succinate for 25 mg.
On the US market
- Reference product
- Toprol-XLNDA 019962
- Approved ANDAs
- 18 with a marketed product
- Approved forms and strengths
- Extended-release tablet 25 mg, 50 mg, 100 mg, 200 mg
- Extended-release capsule 25 mg, 50 mg, 100 mg, 200 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com